HTR1A and Parkinson disease: Although numerous behavioural studies have shown the efficacy of full or partial 5‐HT1A receptor agonists in decreasing dyskinesias, no study has examined how these drugs may affect the altered output basal ganglia activity in Parkinson's disease and l‐DOPA‐induced dyskinesia.